<DOC>
	<DOCNO>NCT01713530</DOCNO>
	<brief_summary>This trial conduct Africa , Europe United States America ( USA ) . The aim trial compare difference change glycosylated haemoglobin ( HbA1c ) insulin degludec/insulin aspart ( IDegAsp ) and/or oral anti-diabetic drug ( OADs ) insulin degludec ( IDeg ) plus insulin aspart ( IAsp ) and/or OADs .</brief_summary>
	<brief_title>A 26-week Trial Comparing Efficacy Safety Insulin Degludec/Insulin Aspart BID Insulin Degludec OD Plus Insulin Aspart Subjects With Type 2 Diabetes Mellitus Treated With Basal Insulin Need Treatment Intensification With Mealtime Insulin</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin degludec , insulin aspart drug combination</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin , Long-Acting</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<criteria>Diagnosis type 2 Diabetes Mellitus discretion investigator least 26 week prior screen ( visit 1 ) Treatment basal insulin least 12 week prior randomisation without metformin , sulphonylurea ( SU ) /glinide , DPP4 inhibitor , alfaglucosidaseinhibitors HbA1c 7.0 % 10.0 % Body mass index ( BMI ) less equal 40.0 kg/m^2 Treatment glucoselowering agent ( ) state inclusion criterion Stroke ; heart failure New York Heart Association ( NYHA ) class III IV ; myocardial infarction ; unstable angina pectoris ; coronary arterial bypass graft angioplasty Chronic disorder disease might jeopardise safety compliance Malignant neoplasm Recurrent severe hypoglycaemia</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>